AAAAAA
Results:
1-7
|
Results: 7
Authors:
Ivleva, AY
Maximenko, OK
Sivkova, EB
Pikalova, NI
Sokurenko, EV
Arutyunov, AG
Citation: Ay. Ivleva et al., Efficacy and tolerability of losartan and its fixed dose combination with hydrochlorothiazide in the treatment of hypertension in patients with high risk of complications, KARDIOLOGIY, 41(1), 2001, pp. 34-38
Authors:
Ivleva, AY
Arutyunov, AG
Citation: Ay. Ivleva et Ag. Arutyunov, The selective angiotensin receptor blocker diovan: Selective, effective, protective, KARDIOLOGIY, 40(11), 2000, pp. 52-53
Authors:
Sidorenko, BA
Ivleva, AY
Karpov, YA
Glezer, MG
Syrkin, AI
Citation: Ba. Sidorenko et al., Valid choice of beta-blockers in the treatment of essential hypertension, TERAPEVT AR, 71(2), 1999, pp. 57-64
Authors:
Ivleva, AY
Sokolova, MA
Moiseev, VS
Citation: Ay. Ivleva et al., A hypotensive effect and tolerance of valsartan (diovan) in essential hypertension, TERAPEVT AR, 71(2), 1999, pp. 67-70
Authors:
Sidorenko, BA
Oganov, RG
Arabidze, GG
Karpov, YA
Doshchitsin, VL
Ivleva, AY
Gratsianskii, NA
Kobalava, ZD
Citation: Ba. Sidorenko et al., The trends in treatment of cardiovascular diseases in the XXI century: Role of angiotensin II blockers receptors - Discussion, KARDIOLOGIY, 39(6), 1999, pp. 86-96
Authors:
Ivleva, AY
Citation: Ay. Ivleva, Pharmacoeconomical basis for the use of ACE inhibitors after myocardial infarction, KARDIOLOGIY, 39(3), 1999, pp. 74-78
Authors:
Ivleva, AY
Citation: Ay. Ivleva, New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan), TERAPEVT AR, 70(9), 1998, pp. 85-88
Risultati:
1-7
|